Diabetes 2 Treatment
Diabetes 2 Treatment questions and answers
Save money by ordering Novorapid 100 mL Online at The Drug Company.
Q: Should people with type 2 diabetes receive expensive treatment?
Do you think that its fair for people with type 2 diabetes to receive expenisive treatment, that people with type 1 could use?
x
A: Just what is the difference. Should we just kill all type 2 diabetics. This is a dumb question. Type 1 take up most of treatment because they are diabetic longer.
Q: Has anyone had positive results with alternative adult onset (type 2) diabetes treatments?
I am interested in finding out any and all alternative (besides the regular medical advice) type 2 diabetes treatments.Any answers are welcome-thanks.
A: Cinnamon capsules can help with blood glucose (works with the pancreas) as well as high cholesterol and high blood pressure levels and it's great for general heart health. In particular if you're gonna eat any sweets take a cinnamon cap about 20 min ahead of time (in addition to daily cinnamon supplements).
The next thing is gymnena (may be hard to get but if you have a good herbal store they should carry it). The gymnema will help your pancreas start doing the correct production of sugar levels. A lot of people have been able to stop any Western Medicine treatment for Type 2.
If you are on Western Medicine treatment make sure you stay well away from grapefruit (in any form).
Also I would highly recommend a Gluten Free diet, it's done wonders for many.
Good luck with your search and I hope some of these suggestions help.
Q: What would happen if you don't take teh treatment for type 2 diabetes?
How long would it take to die also?
A: Type 2 is a condition, and you must take ir very seriously. Diabetes (type 1 or 2) affects everything in your body. Long term, if you're not careful, you can eventually go blind. You can suffer amputations (toes, whole feet and even the leg up to the knee. Cardiac complications, the list never ends. You do what you must to try to delay the inevitable....
Q: I need herbal treatment of Diabetes type- 2 ? I am allergic to most allopathc medicin?
I am allergic to most allopathy medicines. This is great curse on me.
A: There is no herbal treatment for any type of Diabetes, juvenile or adult so your doctor will probably put you on a restricted ADA diet.
Q: what is the progress for a cure or treatment for type 2 diabetes?
how close are we to an all-out cure?
A: A ketogenic diet will help to control NIDDM if you stick to it. It could "cure" almost all type 2 cases. Type 1 is a different story.
Q: I have been offered a Job in Adelaide, I have type 2 diabetes & im worried about treatment & costs.?
I have been told that the condition itself neednt be a problem with the visa but im worried about the cost of my medication and treatment. As it is currently covered by the NHS would it be covered under the reciprocal agreement between the Uk & Australia?
I would move over on a working visa then immediately apply for residence.
A: No - that only applies to holiday visitors - as you will be working you will not be considered a holiday visitor. Are you coming on a PR? If so you will also get a medicare card which reduces the cost substantially. If not you will have to pay full cost.
Q: For Diabetes Treatment, TRIGUNIL 2 IS prescribed by a Doctor. I want details of this medicine.?
A: go to http://www.drugs.com to look up this medicine. All drugs in different countries have different trade names. Not all drugs are available in all countries.
another site to get info on drugs is http://www.webmd.com
Q: if u have type 2 diabetes and u start getting treatment for it will those symptoms go away ?
health
A: Some symptoms will go away. Others may be irreversible.
Q: What can you say about the treatment for type 2 diabetes that could increase the risk for stroke & heart dse.?
A: Having untreated diabetes also increases your risk for heart attack and stroke as well as a number of other conditions. There are other treatments for diabetes that are safe.
Q: Are people with untreated diabetes 2 subject to irrational mood swings?
A close female relative has been diagnosed with diabetes 2. She refuses treatment, and she exhibits ALL of the classical symptons, but in addition is subject to frequent angry and nasty moods. Abusing everybody close to her and being particularly unpleasant while accusing everybody of not liking her. Is this a sympton or cause of the diabetes?
A: I am sorry that a family member has to deal with this the rest of her life. yes irritability is a symptom of the diabetes. usually when the persons blood sugar is to low they can get very aggravated and irritable. she most definitely should start taking her medication and watching what she eats. not only does the medication help to control her blood sugar level it helps to maintain normal functioning of her organs. most people don't know that diabetes affects your kidneys, your eye sight, etc. taking the med's and watching what she eats will prevent the deterioration of such things. good luck do some research it's not as bad as she thinks.
Q: Natural treatment for type 2 diabetes?
Are there vitimines, minerals, herbs that are effective in controling type two diabetes?
A: All I know about is diet, exercise, and medication. ----------------------
Q: has anyone had any success with gluconorm (repaglinide) for treatment type 2 diabetes?
any adverse effects and how long have you been taken them
A: You can treat type 2 diabetes without medications, by changing your lifestyle, "Eat to live not live to eat" ,by eating low carbo high fiber diet, eating a lot of fresh green vegetables , plenty of fresh fruits. and most important exercise /walk.
I have been type 2 diabetic since a year and not using any diabetic medicine and all my levels are within the range. I have shared you my personal experience.
visit my free website http://www.reddiabetes.com for more information.
About gluconorm (repaglinide) following is the detailed information
Repaglinide is an oral blood glucose-lowering drug used in the management of type 2 diabetes mellitus. Repaglinide is a short-acting insulin secretagogue which lowers blood glucose levels (as measured by HbA 1C and fasting plasma glucose) and is effective in regulating meal-related (prandial) glucose loads. Repaglinide lowers blood glucose levels by stimulating the release of insulin from the pancreas. This action is dependent upon functioning beta cells in the pancreatic islets. Insulin release is glucose-dependent and diminishes at low glucose concentrations.
Repaglinide is chemically unrelated to oral sulphonylurea insulin secretagogues used in the treatment of type 2 diabetes.
Repaglinide closes ATP-dependent potassium channels in the b-cell membrane by binding at characterizable sites. This potassium channel blockade depolarizes the b-cell which leads to an opening of calcium channels. The resulting increased calcium influx induces insulin secretion. The ion channel mechanism is highly tissue selective with low affinity for heart and skeletal muscle.
Pharmacokinetics: Absorption: After oral administration, repaglinide is rapidly and completely absorbed from the gastrointestinal tract. After single and multiple oral doses in healthy subjects or in patients, peak drug levels (C max) occur within 1 hour (T max). Repaglinide is rapidly eliminated from the blood stream with a half-life of approximately 1 hour. The mean absolute bioavailability is 56%. When repaglinide was given with food, the mean T max was not changed, but the mean C max and AUC (area under the time/plasma concentration curve) were decreased 20% and 12.4%, respectively.
Distribution: After i.v. dosing in healthy subjects, the volume of distribution at steady state (V SS) was approximately 31 L, and the total body clearance (CL) was 38 L/h. Protein binding and binding to human serum albumin was greater than 98%.
Metabolism: Repaglinide is completely metabolized by oxidative biotransformation and direct conjugation with glucuronic acid after either an i.v. or oral dose. The major metabolites are an oxidized dicarboxylic acid (M 2), the aromatic amine (M 1) and the acyl glucuronide (M 7). The cytochrome P450 enzyme system, specifically 3A4, has been shown to be involved in the N-dealkylation of repaglinide to M 2 and the further oxidation to M 1. Metabolites do not contribute to the glucose-lowering effect of repaglinide.
Excretion: Within 96 hours after dosing with 14C-repaglinide as a single oral dose, approximately 90% of the radiolabel was recovered in the feces and 8% in the urine. Only 0.1% of the dose is cleared in the urine as parent compound. The major metabolite (M 2) accounted for 60% of the administered dose. Less than 2% of parent drug was recovered in feces.
Pharmacokinetic parameters: Data indicate that repaglinide did not accumulate in serum. Repaglinide demonstrated pharmacokinetic linearity over the 0.5 to 4 mg dose range.
The pharmacokinetic parameters of repaglinide obtained from a single-dose, crossover study in healthy subjects and from a multiple- dose, parallel, dose-proportionality (0.5, 1, 2 and 4 mg) study in patients with Type 2 diabetes are summarized in Table I.
Variability: The intraindividual and interindividual variabilities (coefficient of variation) in AUC were 36% and 69%, respectively, after multiple dosing of repaglinide tablets (0.25 to 4 mg with each meal) in patients.
Geriatrics: Healthy volunteers were treated with a regimen of 2 mg taken before each of 3 meals. There were no significant differences in repaglinide pharmacokinetics between the group of patients <65 years of age and a comparably sized group of patients ³65 years of age.
Gender: A comparison of pharmacokinetics in males and females showed the AUC over the 0.5 to 4 mg dose range to be 15 to 70% higher in females with type 2 diabetes. This difference was not reflected in the frequency of hypoglycemic episodes (male: 16%; female: 17%) or other adverse events. With respect to gender, no change in general dosage recommendation is indicated since dosage for each patient should be individualized to achieve optimal clinical response.
Race: No pharmacokinetic studies to assess the effects of race have been performed, but in a U.S. 1-year study in patients with type 2 diabetes, the blood glucose-lowering effect was comparable between Caucasians (n=297) and African-Americans (n=33). In a U.S. dose-response study, there was no apparent difference in exposure (AUC) between Caucasians (n=74) and Hispanics (n=33).
Clinical: A 4-week, double-blind, placebo-controlled dose-response trial was conducted in patients with type 2 diabetes using doses ranging from 0.25 to 4 mg taken with each of 3 meals. Repaglinide therapy resulted in dose-proportional glucose lowering over the full dose range. Plasma insulin levels increased after meals and reverted toward baseline before the next meal. Most of the fasting blood glucose-lowering effect was demonstrated within 1 to 2 weeks.
In a double-blind, placebo-controlled, 3-month dose titration study, repaglinide or placebo doses for each patient were increased weekly from 0.25 mg through 0.5, 1, and 2 mg to a maximum of 4 mg, until a fasting plasma glucose (FPG) level <8.9 mmol/L was achieved or the maximum dose reached. The dose that achieved the targeted control or the maximum dose was continued to end of study. FPG and 2-hour postprandial glucose (PPG) increased in patients receiving placebo and decreased in patients treated with repaglinide. Differences between the repaglinide- and placebo-treated groups were -3.41 mmol/L (FPG) and -5.78 mmol/L (PPG). The between-group change in HbA 1C, which reflects long-term glycemic control, was 1.7% units. See Table II.
Another double-blind, placebo-controlled trial was carried out in 362 patients treated for 24 weeks. The efficacy of 1 and 4 mg preprandial doses was demonstrated by lowering of fasting blood glucose and by HbA 1C at the end of the study. HbA 1C for the repaglinide-treated groups (1 and 4 mg groups combined) at the end of the study was decreased compared to the placebo-treated group in previously naïve patients and in patients previously treated with oral hypoglycemic agents by 2.1% units and 1.7% units, respectively. In this fixed-dose trial, patients who were naïve to oral hypoglycemic agent therapy and patients in relatively good glycemic control at baseline (HbA 1C below 8%) showed greater blood glucoselowering including a higher frequency of hypoglycemia. Patients who were previously treated and who had baseline HbA 1C ³ 8% reported hypoglycemia at the same rate as patients randomized to placebo. There was no average gain in body weight when patients previously treated with oral hypoglycemic agents were switched to repaglinide. The average weight gain in patients treated with repaglinide and not previously treated with sulfonylurea drugs was 3.3%.
The dosing of repaglinide relative to meal-related insulin release was studied in 3 trials including 58 patients. Glycemic control was maintained during a period in which the meal and dosing pattern was varied (2, 3, or 4 meals/day; before meals x 2, 3, or 4) compared with a period of 3 regular meals and 3 doses/day (before meals x 3). It was also shown that repaglinide can be administered at the start of a meal, 15 minutes before, or 30 minutes before the meal with the same blood glucose lowering effect.
Repaglinide was compared to other insulin secretagogues in 1-year controlled trials to demonstrate comparability of efficacy and safety. Hypoglycemia was reported in 16% of 1 228 repaglinide patients, 20% of 417 glyburide patients, and 19% of 81 glipizide patients. Of repaglinide-treated patients with symptomatic hypoglycemia, none developed coma or required hospitalization.
Indications: As an adjunct to diet and exercise to lower the blood glucose in patients with type 2 diabetes mellitus whose hyperglycemia cannot be controlled satisfactorily by diet and exercise alone.
Repaglinide is also indicated for use in combination with metformin to lower blood glucose in patients whose hyperglycemia cannot be controlled by exercise, diet, and either repaglinide or metformin alone. If glucose control has not been achieved after a suitable trial of combination therapy, consideration should be given to discontinuing these drugs and using insulin. Judgments should be based on regular clinical and laboratory evaluations.
In initiating treatment for type 2 diabetes, diet and exercise should be emphasized as the primary form of treatment. Caloric restriction, weight loss and exercise are essential in the obese diabetic patient. Proper dietary management and exercise alone may be effective in controlling the blood glucose and symptoms of hyperglycemia. In addition to regular physical activity, cardiovascular risk factors should be identified and corrective measures taken where possible.
If this treatment program fails to reduce symptoms and/or blood glucose, the use of an oral blood glucose-lowering agent or insulin should be considered. Use of repaglinide must be viewed by both the physician and patient as a treatment in addition to diet, and not as a substitute for diet or as a convenient mechanism for avoiding dietary restraint. Furthermore, loss of blood glucose control on diet alone may
Q: what is the different of treatment between diabetes mellitus type 1 and 2?
pharmacology and non-pharmacology... thanks...
A: Diabetes 1 your body produces no insulin and you must take insulin to keep your blood sugar under control (diet, excercise and oral hypoglycemics will sometimes be given to help control sugars).
Diabetes 2 your body does not produce enough insulin so treatment is aimed at helping your body control sugar ... start by controlling diet, then add oral hypoglycemics (metformin, glyburide, avandia etc...) and insulin only if necessary.
HbAic test to see wether treatment is helping with longterm sugar control.
Hope this helps,
C
Q: do you believe that cinnamon can help in treatment of type 2 diabetes?
A: I read the study that came out about cinnamon. You have to take 1/4 teaspoon of cinnamon every day. The study was for 45 days. They found that after patients went off the cinnamon, their high blood sugar returned. They are still studying the long term possibilities.
Q: Does Type 2 Diabetes ever disappear with treatment?
A: I don't know if "disappear" is the correct term to use here. Type II diabetes is ordinarily associated with obesity and insulin resistance. Insulin levels are actually normal or increased.
A patient who loses weight to a normal level and who eats well and exercises may eliminate the need for diabetic medications. This is not really the same as a cure, though, more of a means to control the problem.
Unfortunately, it is extremely difficult for obese people to lose even modest amounts of weight, and many diabetic medicines lead to a gain in weight.